Navigation Links
VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
Date:4/3/2009

SAN FRANCISCO, April 3 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has received a letter, dated March 31, 2009, from the staff of the NASDAQ Stock Market informing the Company that it does not currently comply with NASDAQ Marketplace Rule 4310(c)(3). NASDAQ Marketplace Rule 4310(c)(3) requires companies maintain either: (i) $2,500,000 in stockholders' equity; (ii) a market value of listed securities of $35,000,000; or (iii) net income from continuing operations of $500,000 in the most recently completed fiscal year or two of the last three most recently completed fiscal years. The Company intends to submit a specific plan to achieve and sustain compliance with the $2,500,000 stockholders' equity standard by April 15, 2009, including the time frame for completion of the compliance plan. If the NASDAQ staff determines that the Company's plan does not adequately address the issue noted above, the NASDAQ staff will provide written notice that the Company's securities will be delisted. At that time, the Company may appeal the NASDAQ staff's determination to a NASDAQ Listing Qualifications Panel (the "Panel"), which would stay any further delisting action by NASDAQ pending a final decision by the Panel. No assurances can be provided that NASDAQ will grant the Company sufficient time to execute its plan to insure that it will maintain its NASDAQ listing.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease. VIA's lead candidate, VIA-2291, targets a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
2. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
3. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
4. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
5. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
6. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
7. VIA Pharmaceuticals to Present Poster at AHA Arteriosclerosis, Thrombosis and Vascular Biology Conference 2009
8. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
9. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
10. Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors
11. VIA Pharmaceuticals Complies With NASDAQ Rules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique ... MabNext project BIOCAD develops a number of innovative drugs ... autoimmune diseases. The ceremony took place at the International ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
(Date:7/10/2014)... help in the fight against terrorism with the creation ... explosives with the use of light and special glass ... Actuators B: Chemical , the researchers describe a novel ... as low as 6.3 ppm (parts per million). It ... , "Traditionally explosives detection has involved looking for metals ...
(Date:7/10/2014)... basis of psychiatric disorders has been extremely challenging because ... but are insufficient to cause disease. Now investigators reporting ... journal Cell Stem Cell describe a strategy ... interact with other risk factors or environmental exposures to ... pinpoints a genetic variant that may predispose individuals to ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Detecting trace amounts of explosives with light 2New strategy could uncover genes at the root of psychiatric illnesses 2
... Medivation, Inc.,(Nasdaq: MDVN ) today announced the ... regulatory and quality, Mohammad Hirmand, M.D., to vice,president, ... translational medicine., "As we enter Phase 3 ... the team to lead and advance our clinical ...
... Biosciences, Inc. (Nasdaq: MGRM ) today announced ... of Vice President, Research and,Development, Oncology. Dr. Parry ... programs, including the further,development of Monogram,s proprietary VeraTag(TM) ... platform - the HERMark(TM) Breast Cancer,Assay., Dr. ...
... with Canadian Division of Global Pharmaceutical,Company, ... BASKING RIDGE, N.J., March 24 /PRNewswire/ ... Millennium Biotechnologies Group, Inc.,(OTCBB: MBTG) announced today ... distribution agreement for Resurgex(R), its nutritional formula,for ...
Cached Biology Technology:Medivation Announces Senior Management Promotions 2Medivation Announces Senior Management Promotions 3Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 2Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 3Monogram Announces Promotion of Gordon Parry, PhD, to Vice President, Research and Development, Oncology 4Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals 2Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals 3
(Date:7/11/2014)... receptor type 1 can inhibit voltage-gated calcium ... neurotransmitter release. However, some scholars demonstrated that ... Ca2+ influx and increase neurotransmitter release. Dr. ... Affiliated to Tongji Medical College, Huazhong University ... cell voltage-clamp and calcium imaging in cultured ...
(Date:7/11/2014)... brains of all vertebrates, information is transmitted through ... chemical signal to be passed from one brain ... most abundant type of synapse, can be either ... learning, memory, perception and cognition, and the balance ... function. For instance, every time we learn ...
(Date:7/10/2014)...  Pomerantz LLP has filed a class action ... "Company")(NYSE-MKT: PVCT) and certain of its officers.  The ... Middle District of Tennessee , ... consisting of all persons or entities who purchased ... 2013 and May 22, 2014, both dates inclusive ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... When battling an epidemic of a deadly parasite, less resistance ... A freshwater zooplankton species known as ... parasite that can infect more than 60 percent of the ... evolves quickly, balancing infection resistance and reproduction. A new ...
... 2012. Metformin, a drug widely used to treat Type II ... the University of Maryland Marlene and Stewart Greenebaum Cancer Center ... Research . Primary liver cancer, or hepatocellular carcinoma, is an ... and is the fastest-growing cause of cancer-related deaths among American ...
... March 30, 2012 The Phoenix Community Alliance (PCA) ... Genomics Research Institute (TGen), with its most prestigious award. ... City Starr Award for his work in improving the ... studying diseases such as Alzheimer,s, diabetes and many types ...
Cached Biology News:Weakness can be an advantage in surviving deadly parasites, a new study shows 2Weakness can be an advantage in surviving deadly parasites, a new study shows 3Commonly used diabetes drug may help to prevent primary liver cancer 2Commonly used diabetes drug may help to prevent primary liver cancer 3Phoenix Community Alliance honors TGen's Dr. Jeffrey Trent 2
... Affinity Life Sciences can provide custom microplate coating using ... washes a variety of plate formats. We can also accommodate ... volume range of 0.5-320 L):, , ... 96 well microplate, ...
... The Bio-Plex maintenance, calibration, and ... custom 96-well plate used for ... calibration procedures using the Bio-Plex ... plate is for use with ...
... sequencing of plasmids and PCR amplicons. ... high performance sequencing pipeline which processes ... day. The key benefits we offer ... rapid turnaround, high sequencing pass rates ...
GLP-compliant, CLIA-certified DNA sequencing service. ASQ and SQA certified quality assurance staff. Auditors welcome....
Biology Products: